Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE: Announces it has co-published a scientific paper on AI to target Ageing
Aladdin Healthcare Technologies SE Announces (BERLIN, Germany and LONDON, England) 12 December 2019, Aladdin Healthcare Technologies SE (“Aladdin”), a leading developer of next generation breakthroughs in age-related disease accelerated by the integration of leading science and AI today announced it has co-published a scientific paper, in the ‘Mechanisms of Ageing and Development’ journal within Science Direct by Elsevier. The paper titled, ‘The NAD+-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications’, delves into the concept that NAD+ could hold the key to early diagnosis and delay of neurodegenerative diseases. The paper focuses on 3 key points: – Summarizing the importance of NAD+ and mitophagy in healthy longevity. – Proposing an NAD+-mitophagy axis in health and disease, especially in neurodegenerative diseases. – Discuss the importance and how to use artificial intelligence (AI) in the NAD+-mitophagy axis-based mechanistic studies, drug development. Advances in our understanding of the molecular and cellular roles of NAD+ in mitophagy will lead to novel approaches for facilitating healthy mitochondrial homoeostasis that may serve as a promising therapeutic strategy to counter ageing-associated pathologies and/or accelerated ageing. The paper shows that by collaborating with academic and medical partners Aladdin is changing the approach to early diagnosis of age-related disease using our AI capability. This forms the foundation for innovation into new products within this market. Please follow this link to access the full paper: https://www.sciencedirect.com/science/article/abs/pii/S004763741930199X
About Aladdin Healthcare Technologies SE End of Media Release Issuer: Aladdin Healthcare Technologies SE Key word(s): Health
12.12.2019 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | info@aladdinid.com |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 934627 |
End of News | DGAP Media |